Tiger Aesthetics Medical, a division of Tiger Biosciences based in Conshohocken, Pennsylvania, has announced a strategic investment in GenesisTissue Inc, an early-stage biotechnology company developing personalized 3D bioprinting technologies for breast reconstruction and cosmetic surgery. The startup is creating solutions for both lumpectomy and mastectomy reconstruction, as well as aesthetic applications. This collaboration extends Tiger Biosciences’ regenerative medicine initiatives and follows the 2025 launch of alloClae, a ready-to-use structural adipose tissue product for body contouring.
The aesthetics arm of Tiger Biosciences is focused on advancing regenerative tissue technologies that integrate with the body’s natural structures. Its adipose-derived alloClae material was designed to provide mechanical support and cushioning where fat tissue normally exists.
“Tiger Aesthetics was founded on the belief that tissue engineering and regenerative therapies will be the future of medical aesthetics,” said Caro Van Hove, President of the division. “This year’s launch of alloClae underscores our commitment to creating advanced treatment options that naturally integrate with the body. GenesisTissue shares our vision, and its 3D bioprinted scaffold represents the kind of bold innovation that will shape a new paradigm for plastic and reconstructive surgery.”
GenesisTissue’s Regenerative Breast Tissue scaffold provides mechanical support for autologous or allogenic fat transfer. Photo via Tiger Aesthetics Medical.
The Pennsylvania-based organization maintains a broad product line that spans breast implants, expanders, fat-grafting systems, and other biologically derived devices. Its investment in GenesisTissue adds a personalized approach to reconstruction by combining biomaterials and 3D bioprinting for patients seeking alternatives to conventional implants.
Bioprinting for personalized reconstruction
GenesisTissue, headquartered in the United States, is developing an advanced 3D bioprinting platform for patient-specific soft-tissue reconstruction. Its system integrates digital surgical planning, precision printing, and biomaterial science to create custom scaffolds designed to support fat-tissue regeneration.
The company’s lead program centers on a degradable scaffold produced through 3D bioprinting. It provides structural integrity immediately after implantation and gradually resorbs as the patient’s tissue replaces it, serving as a potential alternative to silicone gel breast implants.
Breast cancer affects more than 2 million women globally each year, and around 200,000 undergo mastectomy or lumpectomy surgeries annually in the United States. Many of these patients forgo reconstruction due to limited surgical options—especially those treated with lumpectomy, a procedure for which no implant-based solutions currently exist.
Manufacturing on Demand
“At GenesisTissue, we see a future where technology and biology come together to restore confidence, form, and function,” said Katie Weimer, CEO and Co-founder of GenesisTissue. “With advances in 3D bioprinting and material science, we can finally move beyond implants made from industrial materials toward living, regenerative solutions. Every woman deserves the right to a lifelong, natural breast restoration. This is what drives our team every day.”
Katie Weimer, CEO and Co-Founder of GenesisTissue. Photo via Katie Weimer/LinkedIN.
GenesisTissue’s products remain investigational and have not yet received clearance from the U.S. Food and Drug Administration. Both organizations plan to focus on generating clinical data to validate safety, tissue integration, and long-term patient outcomes.
From medical 3D printing to bioprinting inside living systems
GenesisTissue’s origins in regenerative medicine trace back to the career of its CEO and co-founder, Katie Weimer, whose earlier work at 3D Systems helped define the field of medical 3D printing. Weimer led the company’s Regenerative Tissue Program (RTP), which applied 3D modeling, bioprinting, and virtual surgical planning to create patient-specific soft-tissue scaffolds for reconstructive surgery. Her team’s work on bioprinted tissue design and complex surgical visualization—such as the 2016 separation of conjoined twins Jadon and Anias McDonald—demonstrated how digital fabrication could extend from surgical modeling into regenerative medicine.
While GenesisTissue represents an application-driven evolution of regenerative bioprinting, scientific progress is also pushing boundaries inside living cells themselves. Researchers at the J. Stefan Institute and the University of Ljubljana used two-photon polymerization to fabricate microscopic polymer structures directly within living HeLa cells. The work achieved feature sizes below 400 nm, showing that 3D printing can now occur in situ without destroying cellular integrity. Such techniques allow researchers to embed barcodes, microlasers, and mechanical devices directly inside cytoplasm, offering a glimpse of how additive manufacturing may eventually integrate with living biology.
Katie Weimer and Mike Rensberger of 3D Systems hold a 3D printed surgical model used in the operation on conjoined MacDonald twins. Photo via CNN
You might also like:
Human Muscle Tissue 3D Printed in Microgravity by ETH Zurich Researchers: G-FLight: ETH Zurich’s Gravity-Independent Printing System
* This article is reprinted from 3D Printing Industry. If you are involved in infringement, please contact us to delete it.
Author: Anyer Tenorio Lara
Leave A Comment